The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.
Biomedix Incubator Ltd. (TASE:BMDX.M) (formerly Team DCL) announced last week that its incubator company, Israeli biomaterials start-up CollPlant Ltd. has raised $8.3 million in its latest funding round at a value of $38 million. "Globes" first reported that the company was seeking additional funding six months ago. Biomedix holds 20% of CollPlant through Meytav Technological Enterprises Innovation Center Ltd..
CollPlant raised the funding from Pontifax Ltd. owned by Teva chairman Eli Hurvitz, Docor International Management Ltd., and Perrigo deputy chairman Moshe (Mori) Arkin, whose name has been linked to an ever-increasing number of investments in young, publicly traded biomedical companies. Also participating in the round was a European institutional investor, and two unnamed investment funds, one Israeli and the other European.
CollPlant develops plant-derived biomaterials for the healthcare industry. Its first product is collagen, the most commonly found protein in the human body, which is produced directly from humans or another living source.
Published by Globes [online], Israel business news - www.globes-online.com - on April 6, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008